Prometic to conduct PBI-4050 ’s Phase II/III trial for IPF in US

Canada-based Prometic Life Sciences has secured investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to evaluate its drug candidate PBI-4050 in a Phase II/III clinical trial to treat idiopathic pulmonary fibrosis (IP …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

No abstract available
Source: Nursing - Category: Nursing Tags: Department: EDITORIAL Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: DRUG NEWS Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: ETHICS IN ACTION Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: ADVICE P.R.N Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: LEARNING CURVE Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Department: CLINICAL ROUNDS Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Feature: CE Connection Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Feature: CE Connection Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: CE Connection Source Type: research
No abstract available
Source: Nursing - Category: Nursing Tags: Feature Source Type: research
More News: Canada Health | Clinical Trials | Food and Drug Administration (FDA) | Investigational New Drugs | Pharmaceuticals